The innovative gene therapy ABBV-RGX-314 is poised to set a new benchmark in the treatment of wet age-related macular degeneration (AMD).

Ocean Biomedical has expressed its congratulations to its joint venture (JV) partner, Virion Therapeutics.

The proceeds from this offering will fund Stoke's R&D activities, especially for their Dravet syndrome candidate STK-001, preclinical development of ophthalmology candidate STK-002, and other pipeline projects.

PassPort Technologies, Inc. has reported favorable preliminary outcomes from a Phase 1 clinical trial of their Zolmitriptan PassPort® system.

The study combines InnoCare's SHP2 allosteric inhibitor, ICP-189, with ArriVent's furmonertinib, an EGFR inhibitor, for patients with advanced or metastatic NSCLC.

Context Therapeutics Inc. (Nasdaq: CNTX) has submitted an Investigational New Drug (IND) application to the U.S. FDA for CTIM-76.

Surrozen has reported positive preliminary results from its Phase 1a clinical trial of SZN-043, a drug designed to treat severe alcohol-associated hepatitis.

Equillium, Inc., a clinical-stage biotech firm, has reported positive primary results from the Phase 1b EQUALISE study's Type B segment, which assessed the efficacy of itolizumab in lupus nephritis patients.

The pharmaceutical industry is experiencing a surge in the sales of injectable GLP-1 drugs for weight loss, with Eli Lilly's Zepbound recently surpassing Novo Nordisk's Wegovy in new U.S. prescriptions.

The trial will assess the efficacy of BioInvent's monoclonal antibody, BI-1910, when used in conjunction with Merck's KEYTRUDA® (pembrolizumab)

FG-3246 has shown promising results in treating adenocarcinoma within a heavily pre-treated patient group.

Kiromic BioPharma, Inc. has announced early indications of tumor stabilization in a patient enrolled in the Deltacel-01 Phase 1 clinical trial.